Nocturia: An update on diagnosis and treatment
In this video, Alan J. Wein, MD, PhD, discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; and the role of a voiding diary in patient care.
Nocturia has been poorly managed in the past, but renewed interest in its pathophysiology and management has led to improved understanding of this common condition, according to Alan J. Wein, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
In this Urology Times interview, Dr. Wein discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; the role of a voiding diary in patient care; and “quick hits” that he recommends clinicians address first in patients with nocturia.
Dr. Wein is a consultant/adviser or meeting participant for Allergan, Medtronic, Axonics, Outpost, Velicept, Serenity, Aquinox, Avadel, Valencia, and Urovant.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
